**GAP ANALYSIS: WHY DOES THE PROBLEM EXIST?**

1. **Limitations in method to Conduct the Workshop**

I find it difficult to set up a workshop due to limited travel and capacity per session due to the pandemic COVID -19 in 2021 to early 2022. Considering the limited time and resources, the option to hold the workshop in a limited setting could have an impact on the desired outcome of the workshop.

1. **Lack of technical expertise**Hiring a professional consultant can be a valuable resource when revising a national medicines policy. Some of the reasons are:
2. a specialised consultant undertaking the process of reviewing the national medicines policy can bring valuable insights and best practises from other countries or regions that can be applied to the local context.
3. Consultants are free from any political or personal bias. This can help ensure that the policy reviewed is based on sound evidence and is in the best interest of the current system.
4. Reviewing a national medicines policy is a complex process and a time-consuming task. Consultants can provide the necessary time and resources to thoroughly review the policy and ensure that all aspects are considered and evaluated.
5. Stakeholder engagement: Consultants can help facilitate stakeholder engagement and consultation, including the involvement of health professionals, patient groups, pharmaceutical companies and regulators. This can ensure that the policy is informed by a broad range of perspectives and is inclusive of all stakeholders.

Overall, consultants can provide a range of benefits when reviewing a national medicines policy, helping to ensure that the policy is evidence-based, objective, inclusive and ultimately in the best interests of thepopulation.

Limited resources / funding

Limited timeframe for review process

Inadequate data collection

* Review based on existing plan of action.
* Not enough budget
* Changes in gov budget spending policy
* Limited capacity policy due to pandemic
* No thorough situational analysis.
* .

Non - Holistic Medicines Policy Review

* Takes longer time to review.
* Limited capacity policy due to pandemic
* 1st term & 2nd term review done by consultant.
* No experience staff.
* Pharmaceutical sector is indeed complex & consists of many stakeholders.

Complexity of the policy

Implementation challenge

Insufficient expertise